flow trial semaglutide kidney outcomes 2024 nejm hazard ratio in patients with overweight or obesity and chronic disease without diabetes: a randomized double-blind placebo-controlled clinical Top Stories in Nephrology 2024

Embody can prescribe branded medications but they dont dispense brand-name options

Why this matters for India: Generic entry could unlock a 5,000+ crore opportunity over the next 1215 months Prices may drop 3050% initially, and potentially 7075% over time #GLP-1 adoption in diabetes care is expected to rise sharply, adding 0.51% to IPM growth in FY27 Competition is intensifying, with 1015 players vying for share across India, regulated, and emerging markets Novo Nordisk has already launched Ozempic in India (Dec 2025), setting the stage for one of the most closely watched generic transitions in recent pharma history

Every study on the current topic utilized the FDA FAERS database for analyses 32,33,34

Collagen supplementation in skin and orthopedic diseases

To use fat for energy it requires oxygen, so this makes sense